Search people, articles, bills, and more
The Senate rejected an amendment to the federal budget plan that would have authorized a study on the economic impact of confidential drug pricing deals between the government and pharmaceutical companies. The proposal failed 48-50.
This vote was on a proposal by Senator Ron Wyden to modify the 10-year federal budget plan. The amendment sought to create a "reserve fund" to pay for a nonpartisan study by the Government Accountability Office (the Comptroller General). This study would have examined how secret or confidential drug pricing agreements between federal agencies and drug manufacturers affect the broader economy. In the Senate, budget resolutions like this one are often subject to many amendments during a process called a "vote-a-rama." This specific vote required a simple majority to pass, meaning it only needed more "yes" votes than "no" votes. Voting "yes" meant supporting the addition of this drug-pricing study to the national budget framework. The amendment was rejected on a party-line vote, with nearly all Republicans voting against it and Democrats and Independents voting in favor. Because it failed, the study will not be included in this specific budget blueprint. The Senate continued to consider other changes to the broader budget resolution following this result.
The Senate continued to consider other amendments to the broader budget resolution (S.Con.Res. 33) before moving toward a final vote on the entire package.
OPEN BILL →Why it matters. Drug pricing is a major economic issue; this study was intended to provide transparency into how private government deals affect costs.
Who’s affected. Pharmaceutical Companies: Would have faced increased scrutiny regarding their confidential pricing agreements with the government. · Federal Agencies: Would have been required to cooperate with a nonpartisan economic impact study of their contracting practices.
Democrats. The Democratic caucus nearly unanimously supported the amendment, with only one member absent.
Republicans. Republicans overwhelmingly opposed the measure, with only two members crossing party lines to vote 'yes'.
On the Amendment S.Amdt. 5336 to S.Con.Res. 33 (No short title on file)
Apr 23, 2026
The Senate rejected an amendment to the federal budget plan that would have authorized a study on the economic impact of confidential drug pricing deals between the government and pharmaceutical companies.
The proposal failed 48-50.